# Esophagitis

Manage esophagitis by first identifying obstruction, food impaction, bleeding, or malignancy risk, then using upper endoscopy with biopsy to separate reflux, eosinophilic, infectious, pill-related, and motility-associated injury and direct therapy.

**Clinical question:** How should physicians triage, diagnose, and treat esophagitis according to its actionable underlying cause?

Updated: 2026-09-16T00:54:31.105504+00:00

## What matters in practice
- For esophageal dysphagia, perform upper endoscopy with biopsy as the first-line diagnostic test; this identifies structural disease and mucosal etiologies, including eosinophilic esophagitis (EoE). [6][8]
- In food impaction, use flexible upper endoscopy for removal; assess for EoE and other underlying pathology after the acute event. [13]
- Diagnose EoE when esophageal biopsies show at least 15 eosinophils per high-power field after secondary causes of esophageal eosinophilia are excluded. [11]
- For EoE, select anti-inflammatory treatment—PPI, swallowed topical corticosteroid, dietary elimination, or dupilumab—while reserving dilation for clinically significant narrowing because dilation does not control inflammation. [1][19][22]
- Dilate clinically significant EoE strictures toward a 15- to 18-mm diameter, paired with medical or dietary anti-inflammatory therapy. [19]

## Triage dysphagia and choose the first diagnostic test

Separate acute obstruction from chronic inflammatory, structural, and motility-associated presentations.

Treat inability to clear an esophageal food bolus as an endoscopic problem: flexible upper endoscopy is recommended to remove impacted food. After extraction, inspect for rings, narrowing, mucosal injury, and other structural disease; obtain or arrange esophageal biopsy when EoE is a diagnostic consideration. [13]

For esophageal dysphagia outside the immediate food-impaction setting, upper endoscopy with biopsy is the recommended first-line test. It evaluates mucosal injury and structural lesions while detecting esophagitis due to reflux, infection, pills, or eosinophilia before pursuing a motility diagnosis. [6][8]

Do not use a normal-appearing esophagus to exclude EoE. When dysphagia, recurrent food impaction, or an atopic phenotype raises suspicion, obtain esophageal biopsies during endoscopy because histology establishes the eosinophilic inflammatory pattern. EoE requires at least 15 eosinophils per high-power field and exclusion of identified secondary causes of esophageal eosinophilia. [11]
- Acute food impaction: perform flexible upper endoscopy for extraction. [13]
- Esophageal dysphagia: perform upper endoscopy with biopsy before assigning symptoms to a motility disorder. [6][8]
- Persistent heartburn despite evaluation: endoscopy with biopsies is the first step to exclude EoE before reflux monitoring is used to classify functional heartburn. [7]

*Endoscopic findings and clinical context direct the next etiologic branch. [6][8][11][12][19]*

| Pattern at presentation or endoscopy | Diagnostic implication | Next action |
| --- | --- | --- |
| Food impaction or fixed narrowing | Consider EoE-associated fibrostenosis; structural pathology also requires evaluation. [13][19] | Remove the bolus endoscopically; biopsy for EoE and plan anti-inflammatory therapy. Dilate clinically significant stricture when indicated. [13][19] |
| Distal ulcerative esophagitis with stricture | Chronic reflux injury can scar and form a peptic stricture. [12] | Treat reflux with PPI-based healing and maintenance therapy; address recurrent narrowing with dilation strategy as needed. [12] |
| Esophageal eosinophilia of at least 15 eosinophils/high-power field | Supports EoE after secondary causes are excluded. [11] | Choose PPI, swallowed topical corticosteroid, dietary elimination, or selected biologic therapy; assess response with endoscopy and biopsy. [1][13][19][22] |
| No explanatory mucosal or structural cause on endoscopy and biopsy | Motility disease remains a diagnostic branch after structural and mucosal causes have been excluded. [6][8] | Proceed with an esophageal motility evaluation pathway rather than empirically labeling symptoms as reflux. [6][8] |

## Use endoscopy and histology to distinguish the major esophagitis pathways

The treatment target differs substantially among reflux-related, eosinophilic, infectious, pill-related, malignant, and motility-associated disease.

A distal peptic stricture favors chronic reflux-mediated ulcerative esophagitis and scarring. PPI therapy has reduced the incidence of peptic strictures and is central to healing and maintenance of reflux esophagitis; persistent or recurrent dysphagia still requires structural reassessment rather than escalation based on symptoms alone. [12]

EoE is a chronic type 2 inflammatory disease driven by a T-helper 2 response to food antigens in contact with esophageal mucosa. Its clinically important trajectory is from inflammation toward fibrostenotic remodeling, with strictures, luminal narrowing, and a need for dilation in some patients. [3][9]

Infectious, pill-related, radiation-associated, malignant, traumatic or surgical, alcohol-related, and motility-associated esophageal injury are alternative etiologies of esophagitis. Endoscopy with biopsy is the practical discriminator when symptoms or mucosal findings do not fit uncomplicated reflux disease, because it permits direct assessment of the lesion and exclusion of eosinophilic inflammation. [2][6][8]

If dysphagia persists after endoscopy and biopsies have excluded mucosal and structural causes, do not continue an esophagitis-directed pathway without reassessment. Esophageal motility disorders require a separate diagnostic approach after endoscopic exclusion of structural and mucosal disease. [6][8]
- Recurrent solid-food dysphagia, food impaction, rings, stricturing, or eosinophilic histology should shift management toward the EoE pathway. [3][11][19]
- Distal scar-related stricture in the context of chronic ulcerative reflux injury should shift management toward sustained reflux suppression plus management of the narrowing. [12]
- Persistent symptoms with no endoscopic or histologic explanation should trigger motility testing rather than repeated empiric anti-inflammatory escalation. [6][8]

*Management-relevant distinctions among common esophageal injury patterns. [2][3][6][8][11][12][19]*

| Etiologic branch | Discriminator | Management consequence |
| --- | --- | --- |
| Reflux-related esophagitis and peptic stricture | Chronic ulcerative esophagitis can produce distal scarring and stricture. [12] | Use PPI therapy for healing and maintenance; manage a clinically significant stricture mechanically when necessary. [12] |
| Eosinophilic esophagitis | At least 15 eosinophils/high-power field on esophageal biopsy after secondary causes are excluded. [11] | Treat inflammation with PPI, swallowed topical steroid, elimination diet, or selected biologic therapy; add dilation for significant narrowing. [1][19][22] |
| Motility-associated symptoms | Endoscopy and biopsy exclude structural and mucosal causes first. [6][8] | Move to a motility evaluation pathway. [6][8] |
| Infectious, pill, radiation, malignant, traumatic, or surgical injury | Clinical context plus endoscopic and biopsy assessment identifies competing etiologies. [2][6][8] | Direct treatment to the documented injury rather than treating as EoE or uncomplicated reflux. [2][6][8] |

## Treat EoE with an anti-inflammatory strategy and objective reassessment

Symptoms alone do not establish mucosal control or rule out persistent fibrostenotic disease.

Choose initial EoE treatment with shared decision-making among PPI therapy, swallowed topical corticosteroids, and dietary elimination; guidelines and practice patterns recognize these as established therapeutic options, although their sequencing differs across guidance. [1][22] A PPI trial of 20 to 40 mg orally once or twice daily is a reasonable first-line option. [13]

After symptomatic improvement on a PPI, repeat endoscopy with esophageal biopsies to document histologic response. If repeat biopsies show no eosinophils, the clinical framework includes acid-mediated GERD with eosinophilia or PPI-responsive EoE; persistent symptoms and eosinophilia after PPI support an immune-mediated EoE pathway. [13]

For EoE with persistent disease after PPI therapy, swallowed—not inhaled—topical corticosteroid treatment for 8 weeks is a recommended approach. U.S. options described include fluticasone oral suspension 880 to 1,760 mcg/day or budesonide 1 to 2 mg/day. [13] In a randomized trial, budesonide oral suspension 2 mg twice daily produced histologic and clinical remission more often than placebo at 12 weeks, with histologic remission reported in 53.1% versus 1.0%. [18]

Use dietary elimination when a patient prefers a nonpharmacologic anti-inflammatory approach and can sustain the dietary burden. Dietary therapy requires adherence assessment and structured reintroduction to identify triggers; motivation, age, and available educational resources materially affect feasibility. [19][20]

Consider dupilumab for patients needing targeted therapy after inadequate conventional treatment or when treatment selection favors a biologic strategy. Dupilumab is FDA-approved for EoE in patients aged 12 years or older weighing at least 40 kg. [14] In the LIBERTY-EoE-TREET trial, dupilumab 300 mg subcutaneously weekly achieved histologic remission below 6 eosinophils per high-power field in 59.9% versus 5.1% of placebo recipients in one trial part and 58.8% versus 6.3% in another. [19]
- PPI option: 20 to 40 mg orally once or twice daily; repeat endoscopy with biopsy after clinical response. [13]
- Swallowed topical steroid option: fluticasone oral suspension 880 to 1,760 mcg/day or budesonide 1 to 2 mg/day; an 8-week course is described for immune-mediated EoE. [13]
- Dietary option: use an empiric elimination approach only with a plan to assess adherence and systematically reintroduce foods. [19][20]
- Biologic option: dupilumab 300 mg subcutaneously weekly has trial evidence for histologic remission and is FDA-approved in qualifying patients aged at least 12 years and weighing at least 40 kg. [14][19]

### Maintenance and apparent treatment failure

Plan maintenance rather than finite induction alone when remission is achieved, because EoE commonly recurs when therapy is stopped and chronic inflammation can progress to fibrostenotic disease. [3] In randomized withdrawal data, budesonide oral suspension 2 mg daily maintained clinical and histologic remission at week 36 more often than placebo (83.3% versus 50.0%). [18]

For persistent symptoms or histologic inflammation despite PPI, topical steroid, and dietary therapy, first verify the original diagnosis, exclude mimicking conditions, and review the actual treatment history and adherence—especially dietary adherence—before designating disease refractory or changing therapy. [10]
- Do not define control by symptom response alone when histology and endoscopic remodeling remain clinically relevant. Repeat endoscopy with biopsy is used to establish response after PPI therapy. [13]
- Before escalation, verify diagnosis, treatment exposure, and adherence to each attempted therapy. [10]

*Anti-inflammatory EoE options and selection considerations. [1][13][14][18][19][20][22]*

| Option | Supported regimen or selection point | Response assessment or tradeoff |
| --- | --- | --- |
| PPI | 20 to 40 mg orally once or twice daily is a reasonable first-line option. [13] | Repeat endoscopy with biopsy after symptomatic improvement; persistent eosinophilia redirects treatment toward immune-mediated EoE. [13] |
| Swallowed topical corticosteroid | Fluticasone oral suspension 880 to 1,760 mcg/day or budesonide 1 to 2 mg/day; 8 weeks is described for immune-mediated EoE. [13] | Budesonide oral suspension 2 mg twice daily achieved histologic and clinical remission more often than placebo at 12 weeks. [18] |
| Dietary elimination | Select when the patient can sustain restriction and participate in food reintroduction. [19][20] | Adherence and quality-of-life burden are key constraints; reintroduction identifies trigger foods. [19][20] |
| Dupilumab | FDA-approved for EoE in patients aged at least 12 years and weighing at least 40 kg; trial regimen was 300 mg subcutaneously weekly. [14][19] | In phase III trial parts, histologic remission below 6 eosinophils/high-power field occurred in approximately 59% versus approximately 5% to 6% with placebo. [19] |

## Use dilation for obstructive narrowing, not as a substitute for inflammation control

Mechanical therapy relieves luminal obstruction but does not suppress the inflammatory driver of EoE.

Offer esophageal dilation for clinically significant EoE stricture or narrowing causing obstructive symptoms, aiming for a luminal diameter of 15 to 18 mm. [19] Dilation is generally safe, and perforation and bleeding are described as very rare, but it must be performed with recognition that EoE mucosa may be fragile. [19]

Pair dilation with pharmacologic or dietary anti-inflammatory therapy because dilation does not alter EoE pathogenesis or control eosinophilic inflammation. [10][19] Although controlling inflammation before dilation is ideal, timing is not firmly established and clinically important obstruction may require mechanical treatment before full anti-inflammatory response is achieved. [19]

For peptic strictures, reflux suppression remains necessary after mechanical treatment because chronic ulcerative reflux injury is the mechanism of scar formation. Widespread use of PPI healing and maintenance therapy has been associated with a decline in peptic-stricture incidence. [12]
- Indication: clinically significant EoE stricture or narrowing with obstructive symptoms. [19]
- Target: 15 to 18 mm. [19]
- Do not use dilation alone for EoE; continue or initiate an anti-inflammatory treatment plan. [10][19]
- Reassess recurrent dysphagia for persistent inflammation or recurrent narrowing rather than assuming durable disease control after dilation. [10][19]

*Dilation decisions in inflammatory and reflux-related stricturing. [10][12][19]*

| Clinical setting | Role of dilation | Required companion strategy |
| --- | --- | --- |
| EoE with clinically significant stricture | Dilate toward 15 to 18 mm to treat obstruction. [19] | Use PPI, swallowed topical steroid, dietary elimination, or other anti-inflammatory EoE therapy because dilation does not treat inflammation. [10][19] |
| EoE before full inflammatory control | Dilation may still be needed when obstruction is clinically significant; ideal timing remains uncertain. [19] | Initiate or optimize anti-inflammatory treatment and assess response objectively. [19] |
| Peptic stricture | Mechanical management may be needed for narrowing. [12] | Maintain reflux-directed PPI therapy to heal esophagitis and reduce ongoing ulcerative injury. [12] |

## Monitor objective disease activity and escalate persistent dysphagia systematically

Symptoms, histology, and caliber can diverge, particularly in fibrostenotic EoE.

For EoE treated with PPI, repeat endoscopy with biopsies after symptomatic improvement to determine whether eosinophilic inflammation has resolved. [13] This prevents misclassification of persistent eosinophilia as controlled disease and determines whether to continue a PPI-centered strategy or move to swallowed topical steroid, dietary elimination, or biologic therapy. [13][19][22]

If symptoms persist despite an apparently adequate EoE regimen, review diagnostic histology, exclusion of alternative causes, treatment dose and duration, and adherence before escalation. In particular, dietary treatment failure cannot be interpreted without confirming actual avoidance of targeted foods for an adequate interval. [10]

Long symptom duration and diagnostic delay are associated with reduced esophageal distensibility in EoE, reinforcing the need to investigate recurrent dysphagia or food impaction rather than allowing prolonged untreated obstructive disease. [11] When endoscopy and biopsies do not explain dysphagia, redirect the workup to esophageal motility disorders. [6][8]
- Document histologic response with repeat biopsy after a PPI response. [13]
- For persistent symptoms, check diagnostic validity, medication exposure, and dietary adherence before labeling EoE refractory. [10]
- For unexplained persistent dysphagia after endoscopy and biopsy, pursue a motility-disorder evaluation pathway. [6][8]

*Escalation triggers after initial esophagitis evaluation. [6][8][10][11][13][19]*

| Trigger | Interpretation | Next step |
| --- | --- | --- |
| Improved symptoms on PPI but no repeat biopsy | Histologic response remains unknown. [13] | Repeat endoscopy with esophageal biopsies. [13] |
| Persistent EoE symptoms and eosinophilia after PPI | Supports an immune-mediated EoE treatment pathway. [13] | Use swallowed topical steroid, dietary elimination, or selected biologic therapy. [13][19][22] |
| Persistent symptoms after multiple EoE therapies | May reflect incorrect diagnosis, mimicking disease, inadequate exposure, or poor adherence. [10] | Reassess diagnosis and treatment history before changing therapy. [10] |
| Recurrent dysphagia with no mucosal or structural explanation | A motility disorder remains possible after endoscopic exclusion of mucosal disease. [6][8] | Move to esophageal motility evaluation. [6][8] |

## References
1. Real world treatment patterns in patients with eosinophilic esophagitis in Japan | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-78868-4
2. Pinaverium - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/pinaverium
3. Medical and dietary management of eosinophilic esophagitis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1081120618303727
4. Esophageal dilation in eosinophilic esophagitis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521691815001006
5. The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510714001527
6. Esophageal Motility Disorders — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(22)00197-4/pdf
7. AGA Clinical Practice Update on Functional Heartburn: Expert Review — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(20)30128-1/pdf
8. Esophageal Motility Disorders: Current Approach to ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(22)00197-4/fulltext
9. Diagnosis and Treatment of Eosinophilic Esophagitis — www.gastrojournal.org — https://www.gastrojournal.org/article/s0016-5085(17)35950-4/fulltext
10. Managing eosinophilic esophagitis: challenges and solutions - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033215
11. THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC ESOPHAGITIS DISEASE DURATION - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630533
12. Treatment of GERD Complications (Barrett’s, Peptic Stricture) and Extraesophageal Syndromes - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006235?term=%22Best+Pract+Res+Clin+Gastroenterol%22%5Bjour%5D
13. Eosinophilic Esophagitis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459297
14. Eosinophilic esophagitis: promising therapy, biomarkers, and assessment tools | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/page/aaaai-2023/esophagitis
15. Efficacy of Dupilumab in the Treatment of Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11857325
16. Comparative Efficacy of Dupilumab and Standard of Care Treatments for Eosinophilic Esophagitis in Pediatric Patients - Journal of Allergy and Clinical Immunology — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(24)01747-0/fulltext
17. Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11790572
18. Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11283784
19. Recent advances in the treatment of eosinophilic esophagitis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10530275
20. Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/41038415
21. Elimination Diet or Swallowed Topical Steroid Treatment of Pediatric Eosinophilic Esophagitis: Five-Year Outcomes - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2213219823006001
22. Clinical guidance for the use of dupilumab in eosinophilic esophagitis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1081120622019974
23. Childhood Functional Gastrointestinal Disorders: Child — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(16)00181-5/pdf
24. Untangling Nonerosive Reflux Disease From Functional Heartburn — www.gastrojournal.org — https://www.gastrojournal.org/article/S1542-3565(20)30434-1/fulltext

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.